Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1(‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort

PURPOSE: For patients with advanced nonsquamous non‐small cell lung cancer (NSCLC), immunotherapy or antiangiogenic therapy combined with pemetrexed and cisplatin/carboplatin have both shown significant efficacy at programmed cell death ligand 1 (PD‐L1) levels of <1%. Our study aimed to compare t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Ruolan, Li, Yanying, Yang, Ling, Huang, Meijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358234/
https://www.ncbi.nlm.nih.gov/pubmed/37212483
http://dx.doi.org/10.1002/cam4.6101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358234/
https://www.ncbi.nlm.nih.gov/pubmed/37212483
http://dx.doi.org/10.1002/cam4.6101

Ejemplares similares